Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Trial Profile

A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enfortumab vedotin (Primary)
  • Indications Bladder cancer; Carcinoma; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Astellas Pharma Global Development
  • Most Recent Events

    • 06 Jun 2023 Interim results (n=6; As of data cutoff 1 Dec 2022) assessing the safety, PK, and efficacy data for 125mg and 250mg doses of intravesical enfortumab vedotin in patients with non-muscle invasive bladder cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Apr 2023 According to Seagen media release, an abstract (Abstract NO. 4596) including an interim results from this study will be present at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3, 2023, in Chicago.
    • 19 Apr 2023 Trial design presented at the 114th Annual Meeting of the American Association for Cancer Research
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top